Switch theme
Sign up to access all valuation multiples
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
17
Last FY Revenue $1.0M
Last FY EBITDA $48.6M
$208M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Xlife Sciences achieved revenue of $1.0M and an EBITDA of $48.6M.
Xlife Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xlife Sciences valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 66% | XXX | XXX | XXX |
| EBITDA | XXX | $48.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 4851% | XXX | XXX | XXX |
| EBIT | XXX | -$23.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -2317% | XXX | XXX | XXX |
| Net Profit | XXX | $41.2M | XXX | XXX | XXX |
| Net Margin | XXX | 4106% | XXX | XXX | XXX |
| Net Debt | XXX | $70.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Xlife Sciences's stock price is CHF 20 (or $24).
Xlife Sciences has current market cap of CHF 114M (or $137M), and EV of CHF 173M (or $208M).
See Xlife Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $208M | $137M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Xlife Sciences has market cap of $137M and EV of $208M.
Xlife Sciences's trades at 207.4x EV/Revenue multiple, and 4.3x EV/EBITDA.
Equity research analysts estimate Xlife Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xlife Sciences's P/E ratio is not available.
See valuation multiples for Xlife Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $137M | XXX | $137M | XXX | XXX | XXX |
| EV (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 207.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -8.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 3.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -399.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXlife Sciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.4M for the same period.
Xlife Sciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xlife Sciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xlife Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 4851% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2383% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| XXX | XXX | XXX | XXX | XXX | XXX | |
| Waha Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| CVC Capital Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| EXOR | XXX | XXX | XXX | XXX | XXX | XXX |
| Pengana Private Equity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xlife Sciences acquired XXX companies to date.
Last acquisition by Xlife Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Xlife Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is Xlife Sciences headquartered? | Xlife Sciences is headquartered in Switzerland. |
| How many employees does Xlife Sciences have? | As of today, Xlife Sciences has 17 employees. |
| Is Xlife Sciences publicy listed? | Yes, Xlife Sciences is a public company listed on SWX. |
| What is the stock symbol of Xlife Sciences? | Xlife Sciences trades under XLS ticker. |
| When did Xlife Sciences go public? | Xlife Sciences went public in 2022. |
| Who are competitors of Xlife Sciences? | Similar companies to Xlife Sciences include e.g. , Waha Capital, CVC Capital Partners, EXOR. |
| What is the current market cap of Xlife Sciences? | Xlife Sciences's current market cap is $137M |
| Is Xlife Sciences profitable? | Yes, Xlife Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
